KRAS and non-small cell lung carcinoma: This concordance and sensitivity is low in our study compared to a similar study by Han et al. [17] that used an advanced NSCLC cohort (concordance rate 82.0% for EGFR and 85.9% for KRAS; sensitivity 66.7% for EGFR and 50.0% in KRAS).